Development of a technology platform for large-scale clinical grade production of DC
- 1 August 2004
- journal article
- Published by Elsevier BV in Cytotherapy
- Vol. 6 (4), 363-371
- https://doi.org/10.1080/14653240410004934
Abstract
Clinical studies require protocols where a sufficient number of well-characterized highly immunogenic DC are produced according to good manufacturing practice (GMP) guidelines. In the present study, using leukapheresis products from 10 cancer patients, we validated an elutriation technology for large-scale clinical grade production of monocyte-derived DC. The elutriation method gave a very high purity (mean + SD) (86 + 5.3%) and recovery (66 + 10.4%) of monocytes. Specifically for the two monocyte-rich fractions (3 and 4,) the recovery was 42 + 13% of viable cells that could be further differentiated into immature DC in hydrophobic culture bags using GM-CSF and IL-4. The immature DC exhibited < 1% CD83+ expression and >98% phagocytic activity. Maturation with TNF-α or poly I:C resulted in DC with expression of CD80+, CD86+ and HLA-DR+ (> 99%) and CD83+ (80 +11.9%), as well as producing IL-12p70 and lacking phagocytic activity (B/5%). This cell product can be cryopreserved with cell viability > 85% and cell recovery > 80% after thawing. The elutriation procedure, when optimized and if the monocyte content of the starting material exceeds 5%, does not require further selection or depletion using affinity approaches.Keywords
This publication has 20 references indexed in Scilit:
- Gene-modified dendritic cells for immunotherapy against cancerMedical Oncology, 2002
- Dendritic cell maturation in active immunotherapy strategiesExpert Opinion on Biological Therapy, 2002
- A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injectionInternational Journal of Cancer, 2001
- Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapyCytotherapy, 2001
- Dendritic cell vaccination for cancer therapyOncogene, 2000
- Dendritic Cells in Cancer ImmunotherapyAnnual Review of Immunology, 2000
- PBSC harvests individually optimized by using pre-collection CD34+ values and on-line flow cytometric analysis of the mononuclear cell enrichmentCytotherapy, 1999
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- Generation of mature dendritic cells from human blood An improved method with special regard to clinical applicabilityJournal of Immunological Methods, 1996
- Proliferating dendritic cell progenitors in human blood.The Journal of Experimental Medicine, 1994